INS and type 1 diabetes mellitus: Acarbose in T1D: The most important placebo-controlled double-blind intervention study, in which acarbose was administered to 114 adults with T1D, showed a significant reduction in HbA1c (−0.48%; placebo-subtracted), as well as fasting and postprandial hyperglycemia, but with no significant effect on insulin dose, risk of hypoglycemia, body weight, or lipid levels during 24 weeks of treatment.